Free public records show Shanghai MicroPort EP MedTech Co., Ltd. in 2 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Shanghai MicroPort EP MedTech Co., Ltd. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
7 active studies led by Shanghai MicroPort EP MedTech Co., Ltd., of 9 in all
Source: ClinicalTrials.gov, Studies with Shanghai MicroPort EP MedTech Co., Ltd. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
4 510(k) clearances and PMA approvals since 2015
Source: FDA 510(k) and PMA databases, 510(k) clearances, and PMA approvals or changes, since 2015; newest shown. Retrieved 13 Nov 2026.
Studies Shanghai MicroPort EP MedTech Co., Ltd. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Shanghai MicroPort EP MedTech Co., Ltd. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Shanghai MicroPort EP MedTech Co., Ltd.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Shanghai MicroPort EP MedTech Co., Ltd. is in.
Stories on the topics Shanghai MicroPort EP MedTech Co., Ltd. works in.
Omega-3 supplements are hugely popular. Big trials give mixed answers on whether they protect the heart.
Read
More than 300 million operations are done each year, and many no longer need an overnight stay. Ambulatory…
Read
Cardiovascular disease is the world's leading cause of death, and stroke caused 11.9 million new cases in…
ReadSearch all reports for Shanghai MicroPort EP MedTech Co., Ltd. All companies